Trial reportPsychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors2022
Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder.
Trial report in Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01675661 (Achieving Cannabis Cessation), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT)
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Pharmacotherapies for cannabis use disorder.The Cochrane database of systematic reviews · 2025Pooled it
- A preliminary randomized controlled trial of repetitive transcranial magnetic stimulation applied to the left dorsolateral prefrontal cortex in treatment seeking participants with cannabis use disorder.Drug and alcohol dependence · 2024Trial
- Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022Trial
- Beyond abstinence: Redefining success in cannabis use disorder treatment.Addiction (Abingdon, England) · 2026Article
- Behavioral and Functional Neuroimaging Effects of Delivering a Course of Repetitive Transcranial Magnetic Stimulation to Personalized Targets Within the Ventrolateral Or Dorsolateral Prefrontal Cortex in Treatment-Seeking Participants with Cannabis Use Disorder.medRxiv : the preprint server for health sciences · 2026Article
- The measurement of harm reduction goals and outcomes for substance use: Current state and future directions.Journal of prevention and health promotion · 2026Article
- The cannabis-mind connection: a clinician's perspective on mental health practice, harm reduction, and racial equity.Journal of cannabis research · 2025Review
- Implementation and evaluation of a knowledge translation process to optimize the adoption of harm reduction in cannabis use by practitioners working with youth in Quebec: a mixed-methods study.Health research policy and systems · 2025Article
- Mixed-methods study on professionals' attitudes toward harm reduction in cannabis use and the development of a knowledge translation plan.Scientific reports · 2025Article
- Quantity of delta-9-tetrahydrocannabinol consumption and cannabis use disorder among daily cannabis consumers.Addiction (Abingdon, England) · 2025Article
- Exploring heterogeneity in recovery from substance use disorder following mindfulness-based relapse prevention: A latent profile analysis.Journal of substance use and addiction treatment · 2025Article
- Drug-Use Safety Enhancement Model-Theory and Application.Public health challenges · 2024Article
- Association of Cannabis Use Reduction With Improved Functional Outcomes: An Exploratory Aggregated Analysis From Seven Cannabis Use Disorder Treatment Trials to Extract Data-Driven Cannabis Reduction Metrics.The American journal of psychiatry · 2024Article
- Facilitators of and barriers to healthcare providers' adoption of harm reduction in cannabis use: a scoping review protocol.BMJ open · 2024Article
- Is it time for a cannabis harm reduction approach? Commentary on Sherman et al. (2022) and Borodovsky et al. (2022).Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2023Review
- Implementation and Preliminary Evaluation of a 12-Week Cognitive Behavioural and Motivational Enhancement Group Therapy for Cannabis Use Disorder.Substance abuse : research and treatment · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveAbstinence is rarely achieved in clinical trials for cannabis use disorder (CUD). Cannabis reduction is associated with functional improvement, but reduction endpoints have not been established, indicating a need to identify and validate clinically meaningful reduction endpoints for assessing treatment efficacy.
methodData from a 12-week double-blind randomized placebo-controlled medication trial for cannabis cessation (NCT01675661) were analyzed. Participants (
resultsCannabis risk levels were sensitive to reductions in use from BL to EOT for frequency- (
conclusionsCannabis use risk levels, as operationalized in this study, captured reductions in use during a clinical trial. Risk level reduction was associated with functional improvement suggesting that identifying risk levels and measuring the change in levels over time may be a viable and clinically meaningful endpoint for determining treatment efficacy. (PsycInfo Database Record (c) 2022 APA, all rights reserved).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.